Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.94 USD | +0.45% | +2.16% | -12.41% |
05-10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
05-10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.41% | 91.1B | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating